Guangdong Taienkang Pharmaceutical Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Guangdong Taienkang Pharmaceutical Co., Ltd. (hereinafter referred to as "Taienkang"), stock code 301263. Taienkang was established in 1999. Its main business includes agency operation, research and development, production, sales of pharmaceutical products, medical devices, and hygiene materials, as well as providing pharmaceutical technology services and technology transfer. Its main products include Hewei Intestine Pills, "Waritin" Lecithin Complex Iodine Tablets, and "Aitingjiu" Hydrochloride Dapoxetine Tablets. Since its establishment, Taienkang has been acting as an agent for the operation of Weizhengchang Pills and Valantine. As the only general agent in China, it is fully responsible for customs clearance, inspection, market promotion, dealer selection, sales pricing, and other work in the Chinese market. It has also promoted its operations into well-known products in the fields of gastroenterology and ophthalmology in China. After more than 20 years of marketing and promotion, the company has formed a large-scale sales channel network and team. Through strong internal and external channel control capabilities and innovative drug promotion models, the product can quickly achieve sales revenue after being launched. The company established its research and development subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. in 2015. Based on the research and development strategy of "innovative drug research and development as the pinnacle, improved new drugs and biopharmaceuticals as the tower body, and generic drugs as the tower base", functional excipients and nanodrug delivery technology platforms, biological macromolecular drug technology platforms, and generic drug development and consistency evaluation technology platforms have been established. The independently developed "Aitingjiu" hydrochloric acid dapoxetine tablets are the "first imitations" in China, and Tadalafil has obtained drug registration approvals, In 2018, we obtained the first clinical trial approval for injectable docetaxel polymer micelles in China and signed a project transfer agreement with Fosun Pharmaceutical. In addition, the company also has a large reserve of independent drug research and development projects, including Pramipexole Hydrochloride Sustained Release Tablets, Ornidazole Injection, and Agatroban Injection, which have already submitted drug registration approval applications. Leizumab Injection is about to apply for clinical trials. In the next three years, the company is expected to have its research varieties approved for listing every year, which will continuously drive the enrichment of the company's product pipeline and rapid growth of profitability. Taienkang has more than 100000 m2 of industrial land for production, which can meet the production needs of the company's existing and future products. It has strong independent production capacity, and will further improve the production layout of raw materials, chemical drugs, biological drugs, and traditional Chinese patent medicines and simple preparations. During the epidemic period, the company played a role as a fighting fortress for grassroots party organizations and a vanguard and exemplary role for party members, actively expanding the production of epidemic prevention materials, and making significant contributions to the resumption of work and production after epidemic prevention and control and the alleviation of the epidemic. In the future, the company will adhere to the strategy of endogenous growth, extensional expansion, and integrated development, fully utilizing the company's successful capital market platform on the Growth Enterprise Market, leveraging the capital market, with innovation as the core development, continuing to deeply cultivate the pharmaceutical industry, and comprehensively improving its operational level. By independently developing and producing pharmaceutical products that meet market demand, enriching product structure, improving product core competitiveness, fully participating in market competition, we strive to become an innovative and comprehensive pharmaceutical enterprise that integrates research, production, and sales. |
| Headquarter | Shantou |
| Establish Date | 1/22/1999 |
| Listed Code | 301263.SZ |
| Listed Date | 3/29/2022 |
| Chairman | Zheng Hanjie. |
| CEO | Zheng Hanjie. |
| Website | www.tai-kang.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
